AUG 14, 2018 11:40 PM PDT

Using Arsenic to Enhance Cancer Therapies Beyond Leukemia

WRITTEN BY: Mauri Brueggeman

Arsenic is anecdotally known to many as a poison, but it has historically been a potent chemotherapy agent.  Chemotherapies are basically controlled poisons; it is not so far-fetched to think of arsenic in these terms.  Originally used to treat leukemia in the nineteenth century, known as Fowler’s solution, arsenic continues to be investigated and used in conjunction with all-trans retinoic acid (ATRA) for the treatment and cure of Acute Promyelocytic Leukemia (APL).  Specifically, arsenic trioxide (ATO) is the active component needed to promote the anti-leukemic process in the body.  ATO acts on APL by destroying the main fusion protein called PML-RARα which is the disease driving genetic change causing the arrest of myelocytic cell differentiation.  Myelocytic cells need retinoic acid, or vitamin A, to continue developing into mature neutrophils which is why ATRA was used in the first place. 

A recent study published in Nature Communications outlines how ATO and ATRA together target an oncogenic signaling regulator called Pin1.  Pin1 activity is documented in multiple cancers besides leukemia including breast and liver solid tumors.  ATO has been found to degrade Pin1 and ATRA controls the cell’s ability to take up ATO when it is in the body.    

This is an emerging area of research because solid tumors are challenging to target; tumors are often found to utilize multiple activation pathways to remain viable and support their rapid growth.  Blocking one pathway may not work but finding the target that drives a multitude of signaling mechanisms, like in the case of Pin1, provides promise.  ATO and ATRA together have been proven safe at clinical doses and inhibited triple negative breast cancer cells as well as other tumor initiating cells in animal models. 

In vivo studies and clinically relevant data have demonstrated the viability and efficacy of using arsenic in conjunction with other therapeutic agents, like in the case of ATO-ATRA and APL.  Because this combination was found to impede further tumor growth via tumor initiating cells, the tumor’s normal renewal and progression process is disrupted.  In fact, the authors found that Pin1 is “highly enriched” in breast tumor initiating cells and propose further study on whether Pin1 inhibitor drugs could target these specific breast tumor cells.

Sources: Nature Communications, Pathology Outlines, Nature Medicine, Journals of Hematology & Oncology,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
APR 01, 2021
Plants & Animals
Scientists Solve Sea Lion Cancer Mystery
APR 01, 2021
Scientists Solve Sea Lion Cancer Mystery
For more than thirty years, scientists have tried to solve the mystery of the high prevalence of cancer among wild Calif ...
APR 14, 2021
Cancer
Cell Viability- Where to Begin?
APR 14, 2021
Cell Viability- Where to Begin?
Written By: Author As I pondered the title of this article, my thoughts immediately went back to a request by my Ph.D. a ...
APR 03, 2021
Cancer
New factor plays a key role in immune response
APR 03, 2021
New factor plays a key role in immune response
In a study published recently in Science Immunology, WEHI’s Professor Stephen Nutt, Dr. Michael Chopin, and Mr. Sh ...
MAY 06, 2021
Cell & Molecular Biology
Improved Genetic Technologies Find Elusive Genetic Mutations
MAY 06, 2021
Improved Genetic Technologies Find Elusive Genetic Mutations
Some genetic diseases are caused by inborn errors - genetic mutations that we're born with and that end up in every cell ...
MAY 31, 2021
Immunology
Engineering Faster, More Agile T Cell Cancer Fighters
MAY 31, 2021
Engineering Faster, More Agile T Cell Cancer Fighters
Cell therapies use engineered T cells extracted from the patient’s own immune system to rally an attack on tumors. ...
JUN 16, 2021
Cell & Molecular Biology
A Potential Way to Prevent Metastatic Cancer
JUN 16, 2021
A Potential Way to Prevent Metastatic Cancer
Metastatic cancer is the deadliest, and it can happen years after cancer has been treated to the point of remission. Met ...
Loading Comments...